By Colin Kellaher
Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare genetic skin disorder dystrophic epidermolysis bullosa, or DEB.
Krystal on Friday said the recommendation covers Vyjuvek for the treatment of wounds in people with DEB who have mutations in the collagen type VII alpha 1 chain gene, starting from birth.
The Pittsburgh biotechnology company said it expects a final decision from the European Commission, which generally follows the CHMP's advice, in the second quarter.
Krystal, which won U.S. Food and Drug Administration approval of Vyjuvek in 2023, recorded $290.5 million in net product revenue for the drug last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 28, 2025 07:58 ET (12:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。